Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 16, Issue 5, Pages 639-641Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2018.0039
Keywords
-
Categories
Funding
- Bristol-Myers Squibb Company
- Eisai Inc.
- Exelixis Inc.
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Roche Laboratories, Inc.
Ask authors/readers for more resources
Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment-ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting-was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available